ONC018: Expanded Access to ONC201 for Patients with H3 K27M-mutant and/or Midline High Grade Gliomas
Categories (click each to see list of all clinical trials associated with that category): Brain/Neuro
Current Status: Open to accrual
Phase: II
Principal Investigator: Shonka, Nicole
Contact Information:
Sarah Kirke, RN
402-559-8065
sarah.kirke@unmc.edu
Eligibility: https://clinicaltrials.gov/ct2/show/NCT03134131#eligibility
Summary
The objective of this expanded access program is to provide ONC201 to eligible patients with previously-treated glioma that exhibits the H3 K27M mutation and/or that is located in the midline region of the brain.